Boston Scientific Corp. (BSX) recently received the U.S. Food and Drug Administration (FDA) approval for its Express LD Iliac Premounted Stent System for use in iliac arteries. Boston expects to launch the product immediately in the U.S. 

The Express LD Iliac Premounted Stent is already approved for iliac use in several international markets. Furthermore, the stent has received the CE Mark approval for sale in European markets. However, it is the first and only low-profile, premounted, balloon-expandable stent approved by the FDA for treating iliac artery disease in the U.S. 

Atherosclerotic iliac disease occurs when plaque builds within the arteries. This can lead to poor blood flow, leg pain and other complications. The disease can be treated with medication, surgery or angioplasty. 

The Express LD Iliac Premounted Stent System has a tandem architecture stent design that balances strength, flexibility and conformability. The stent offers physicians a less-invasive alternative to surgery for patients suffering from iliac artery disease. 

The new product expands Boston’s portfolio of peripheral vascular stent indications, which include the Carotid WALLSTENT Endoprosthesis for carotid artery disease and the Express SD Stent for renal artery disease. This also reinforces Boston’s leadership position in the treatment of peripheral artery disease. 

Boston is the market leader in the stent market with a 46% market share for its TAXUS DES in the U.S. and 39% globally. 

Boston Scientific manufactures medical devices and products used in a broad range of interventional medical specialties. The company faces significant competition across its product portfolio and its primary competitors include Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ). 

Presently, we are ‘Neutral’ on Boston Scientific Corp.
Read the full analyst report on “BSX”
Read the full analyst report on “JNJ”
Read the full analyst report on “MDT”
Read the full analyst report on “ABT”
Read the full analyst report on “STJ”
Zacks Investment Research